New data suggests that KRAS-mutated lung adenocarcinoma can exhibit enhanced PD-L1 expression and additional somatic mutations, linking the prospect of immune checkpoint blockade therapy being applied to the disease. This evidence concerns the gene KRAS and lung adenocarcinoma.